MRI引导下前列腺穿刺活检:多参数MRI无可见靶区正常表现区域的补充非靶向取材回顾性观察研究
回顾性分析59例在3-T MRI下行MRI引导下前列腺活检并额外对无可见MR靶区(PI-RADS v2 1或2类)随机取材的患者,无可见MR靶区对全部癌和临床显著癌(Gleason≥7)的阴性预测值分别约78%和88.1%,作者认为该人群仍需对无可见MR靶区额外活检。
要点
- 无可见MR靶区对临床显著癌的阴性预测值约88.1%,但仍有9.8%无靶区取材为临床显著癌。
- 初诊患者无靶区对全部癌的阴性预测值仅62.5%,低于既往穿刺阴性(83.3%)和阳性(84.2%)患者。
- 作者认为MR可疑病灶患者中无可见MR靶区仍可能藏有临床显著癌,需对该人群额外活检。
核心结论
- 无可见MR靶区的区域仍可能藏有临床显著癌,可能显著影响治疗决策。
- 作者认为在该人群中应对无可见MR靶区进行额外活检。
研究设计与样本
- 回顾性分析在3-T MRI下行MRI引导下活检并对无可见MR靶区(PI-RADS v2 1或2类)额外随机取材的患者。
- 共纳入59例连续患者,中位年龄65岁(IQR 59–71岁),中位前列腺特异性抗原7 ng/mL(IQR 4.9–10.8 ng/mL)。
- 59例中初诊16例(27.1%),既往经直肠超声引导活检阴性24例(40.7%),既往经直肠超声引导活检阳性19例(32.2%)。
- 临床显著癌定义为Gleason评分≥7,阴性预测值按患者既往活检状态分层,采用描述性分析。
诊断标准与关键数值
- 无可见MR靶区定义为PI-RADS v2 1或2类。
- 临床显著癌定义为Gleason评分≥7。
- 共活检112个无可见MR靶区,其中癌20个(17.9%),临床显著癌11个(9.8%)。
- 无可见MR靶区对全部癌的阴性预测值约78%,对临床显著癌为88.1%。
- 初诊、既往活检阴性、既往活检阳性患者无靶区对全部癌的阴性预测值分别为62.5%、83.3%、84.2%,对临床显著癌分别为75.0%、91.7%、94.7%。
临床应用与阅片要点
- 作者认为对MR可疑病灶患者,无可见MR靶区仍可能藏有临床显著癌,需对无可见MR靶区额外活检。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate the pathologic outcomes of additional random biopsies from areas with no visible MR targets in the setting of targeted in-bore MRI-guided biopsy and to assess the negative predictive value (NPV) of areas with no visible MR targets stratified according to patients' different biopsy statuses.
MATERIALS AND METHODS: A retrospective analysis of patients who underwent in-bore MRI-guided biopsy with additional random biopsies in areas with no visible MR targets (Prostate Imaging-Reporting and Data System, version 2 category 1 or 2) was conducted in this study. Diagnostic scans and in-bore MRI-guided biopsy were performed with a 3-T MRI scanner. Areas with no visible MR targets were biopsied in a random fashion whenever a zone or side did not have a visible focal target. Clinically significant cancers (CSCs) were defined as a Gleason score of 7 or greater. NPVs were stratified based on patient's prior biopsy status. Descriptive analysis was performed.
RESULTS: A total of 59 consecutive patients were included, with a median age of 65 years (interquartile range [IQR], 59-71 years). The median prostate-specific antigen level was 7 ng/mL (IQR, 4.9-10.8 ng/mL). Of the 59 patients, 16 (27.1%) were biopsy naive, 24 (40.7%) had prior negative transrectal US-guided biopsy findings, and 19 (32.2%) had prior positive transrectal US-guided biopsy findings. Forty-two (71.2%) biopsies revealed prostate cancer. A total of 112 areas with no visible MR targets were biopsied, of which 20 (17.9%) were cancers and 11 (9.8%) were CSCs. The NPV of areas with no visible MR targets was approximately 78% for all cancers and was 88.1% for CSCs. NPVs in biopsy-naive patients, patients with prior negative transrectal US-guided biopsy findings, and patients with prior positive transrectal US-guided biopsy findings were 62.5%, 83.3%, and 84.2%, respectively, for all cancers and 75.0%, 91.7%, and 94.7%, respectively, for CSCs.
CONCLUSION: Areas with no visible MR targets in patients with MR-suspicious foci may still harbor CSCs that may significantly affect management plans. Additional biopsies from areas with no visible MR targets are warranted in this population.Keywords: Biopsy/Needle Aspiration, Interventional-Body, MR-Imaging, Prostate, Urinary© RSNA, 2019.
引用
- Elfatairy KK, Filson CP, Sanda MG, et al. In-Bore MRI-guided Prostate Biopsies: Retrospective Observational Study of Complementary Nontargeted Sampling of Normal-appearing Areas at Multiparametric MRI. Radiol Imaging Cancer. 2019. PMID: 33778681. doi:10.1148/rycan.2019190016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。